Chronic Kidney Diseases Clinical Trial
— PRIMETIME2Official title:
Biopsy-proven Diabetic Nephropathy in People With Type 2 Diabetes. Prevalence and Predictive Factors
a prospective, observational, multi-center study with a cohort of 300 patients with Type 2 diabetes and macroalbuminuria. Prospectively we will collect kidney biopsies and analyse the transciptome of the kidney tissue and other biomarkers from blood, faeces, urine, proteomic- and metabolomic profiles and DNA-variants. Thereby we hope to be able to discover molecular and clinical profiles, that can help us in the diagnosis of DKD, and to identify different risks of progression that can benefit from different forms of personalized treatment.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | December 31, 2043 |
Est. primary completion date | December 31, 2043 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years to 120 Years |
Eligibility | Inclusion Criteria: - Age = 18 years - Written informed consent - Diagnosis with T2DM according to the American diabetes Association (20) - eGFR >30 mL/min/1.73 m2 (maximum six months old) - urine-albumin/creatinine-ratio (uACR) > 700 mg/g or 24 hours urine albumin >700 mg on more than one measurement Exclusion Criteria: - Signs of acute kidney failure according to the KDIGO classification (21) at the time for kidney biopsy or the last 6 months before kidney biopsy - Factors that increases the risk of complications due to kidney biopsy: - Hemoglobin < 6 mmol/L - INR >1,4 at the time for biopsy - Platelet count < 100 x 109/l - Uncontrolled high blood pressure (defined as systolic blood pressure > 160 mmHg and/or diastolic blood pressure > 100 mmHg) - Only one functioning kidney - Evidence of urinary tract obstruction or hydronephrosis at the time of biopsy - Multiple bilateral kidney cysts - Kidney infection, peri-renal infection, or cutaneous infection that overlies the kidney at time for biopsy - Unwilling to receive blood transfusion - Unable to lie flat in bed six hours after biopsy - Any other contra-indications for percutaneous kidney biopsy according to local clinical guidelines - Unable to understand written and oral information - Kidney transplant recipient - Previous medical kidney biopsy - Women who are pregnant or planning to become pregnant before the kidney biopsy is performed - Treatment with Marcoumar (all other anticoagulants are accepted) - High thromboembolic risk combined with held in anticoagulation therapy according to the report "Perioperative regulation of antithrombotic treatment" (PRAB) (22) - mechanical heart valve - atrial fibrillation AND CHA2DS2-VASc> 5 and/or stroke within the last three months - recurrent venous thromboembolism OR venous thromboembolism within the last three months - less than 6 weeks after uncomplicated Acute Coronary Syndrome (ACS) with or without revascularization (Percutaneous Coronary Intervention (PCI)) with Bare Metal Stents (BMS) or Coronary Artery Bypass Grafting (CABG)) - less than 3 months after uncomplicated ACS with revascularization (PCI with Drug Eluting Stent (DES)) - less than 9-12 months after complicated ACS (e.g. reinfarction or stent thrombosis) - less than 1 month after revascularization in individuals with stable Coronary Artery Disease (CAD) (PCI with BMS or CABG) - less than 3 months after revascularization in individuals with stable CAD (PCI with DES) - less than 3 months after stroke, or Transient Ischemic Attack (TIA) - Inability to withdraw nonsteroidal anti-inflammatory drugs (NSAID) 7 days before biopsy If a participant meets one or more exclusion criteria, that are reversible, the participant can be rescreened later on, to evaluate whether or not the participant now is qualified for participation. |
Country | Name | City | State |
---|---|---|---|
Denmark | Aalborg universitetshospital | Aalborg | |
Denmark | Rigshospitalet | Copenhagen | København Ø |
Denmark | Steno Diabetes Center Copenhagen | Copenhagen | Gentofte |
Denmark | Regionshospitalet Gødstrup | Gødstrup | |
Denmark | Herlev Hospital | Herlev | |
Denmark | Kristine D Schandorff | Hillerød | |
Denmark | Holbæk Hospital | Holbæk | |
Denmark | Sjællands Universitetshospital, Køge | Køge | |
Denmark | Nykøbing Falster Sygehus | Nykøbing Falster | Nykøbing F |
Denmark | Odense universitetshospital | Odense | |
Denmark | Sjællands Universitetshospital, Roskilde | Roskilde | |
Denmark | Aarhus Universitetshospital, Skejby | Skejby | Aarhus |
Denmark | Slagelse Sygehus | Slagelse |
Lead Sponsor | Collaborator |
---|---|
Herlev Hospital | Aalborg University Hospital, Aarhus University Hospital, Gødstrup Hospital, Gubra ApS, Hillerod Hospital, Denmark, Holbaek Sygehus, Michigan Kidney Translational Medical Center, Novo Nordisk A/S, Nykøbing Falster County Hospital, Odense University Hospital, Rigshospitalet, Denmark, Slagelse Sygehus, Steno Diabetes Center Copenhagen, Steno Diabetes Center Nordjylland, Steno Diabetes Center Sjaelland, The Novo Nordisk Foundation Center for Basic Metabolic Research, Zealand University Hospital |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Prevalence | To investigate the prevalence of biopsy-proven diabetic nephropathy in individuals with T2DM with severe albuminuria; urine albumin/creatinine ratio (UACR) >700 mg/g. | From baseline to end inclusion (3 years) | |
Secondary | Improved clinical diagnosis | To investigate whether clinical variables, transcriptomic, proteomic and/or metabolomic profiles as well as genetic variation can predict the presence of diabetic nephropathy in a kidney biopsy. | From baseline to end inclusion (3 years) | |
Secondary | diabetic retinopathy | To describe the sensitivity and specificity of diabetic retinopathy in predicting biopsy-proven diabetic nephropathy | From baseline to end inclusion (3 years) | |
Secondary | Kidney Biopsy | describe the prognostic value of different histological and molecular findings on kidney biopsy in individuals with biopsy-proven diabetic nephropathy | From baseline to end of followup (20 years) | |
Secondary | non-diabetic nephropathy vs. biopsy-proven diabetic nephropathy | describe the prognostic value of different histological and molecular findings on the kidney biopsy in individuals with non-diabetic nephropathy compared to biopsy-proven diabetic nephropathy. | From baseline to end of followup (20 years) | |
Secondary | proteomic and metabolomic | describe the prognostic value of the proteomic and metabolomic profiles in biopsy-proven diabetic nephropathy. | From baseline to end of followup (20 years) | |
Secondary | genetic variants | describe the prognostic value of different forms of genetic variation in biopsy-proven diabetic nephropathy | From baseline to end of followup (20 years) | |
Secondary | Microbiome | describe the prognostic value of different compositions of the microbiome and its relation to biopsy and clinical findings | From baseline to end of followup (20 years) | |
Secondary | Annual changes in kidney status | Annual changes in kidney status (defined by yes/no: initiation of dialysis, kidney transplantation, renal death or decrease in eGFR > 40 % compared to eGFR at baseline) | From baseline to end of followup (20 years) | |
Secondary | Annual decline in eGRF | Annual decline in eGRF | From baseline to end of followup (20 years) | |
Secondary | Annual changes in albuminuria. | Annual changes in albuminuria. | From baseline to end of followup (20 years) | |
Secondary | Annual events of cardiovascular disease | Events of cardiovascular disease (fatal CV events, non-fatal stroke, non-fatal myocardial infarction, hospitalization for heart failure, PCI or bypass surgery (heart or legs), amputations due to ischemia, and unstable angina) | From baseline to end of followup (20 years) | |
Secondary | Death | Death (any cause). | From baseline to end of followup (20 years) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06386172 -
Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm
|
N/A | |
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT03434145 -
Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases
|
N/A | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Terminated |
NCT05022329 -
COVID-19 Vaccine Boosters in Patients With CKD
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Recruiting |
NCT04961164 -
Resistant Starch Prebiotic Effects in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05015647 -
Low Protein Diet in CKD Patients at Risk of Malnutrition
|
N/A | |
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT04831021 -
Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?
|
N/A | |
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT04422652 -
Combination of Novel Therapies for CKD Comorbid Depression
|
Phase 2 | |
Completed |
NCT05055362 -
Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
|
N/A | |
Not yet recruiting |
NCT06330480 -
Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT03176862 -
Left Ventricular Fibrosis in Chronic Kidney Disease
|
N/A | |
Terminated |
NCT02539680 -
Intestinal Phosphate Transporter Expression in CKD Patients
|
N/A |